Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP)

被引：0
|
作者：
Hassel, J. [1 ,2 ]
Forschner, A. [3 ]
Bluhm, L. [4 ]
Heinzerling, L. [5 ]
Zimmer, L. [6 ]
Utikal, J. [7 ,8 ]
Kaehler, K. [9 ]
Schlaak, M. [10 ]
Loquai, C. [11 ]
Gutzmer, R. [12 ]
Kieker, F. [13 ]
Berking, C. [14 ]
Bender, A. [15 ]
Schneider, L. [16 ]
Enk, A. [1 ,2 ]
Garbe, C. [3 ]
Weichenthal, M. [9 ]
Schadendorf, D. [6 ]
Hauschild, A. [9 ]
Mohr, P. [4 ]
机构：
[1] Univ Klinikum Heidelberg, Hautklin, Heidelberg, Germany
[2] Univ Klinikum Heidelberg, NCT, Heidelberg, Germany
[3] Univ Klinikum Tubingen, Hautklin, Tubingen, Germany
[4] Elbe Klinikum Buxtehude, Hautklin, Buxtehude, Germany
[5] Univ Klinikum Erlangen, Hautklin, Erlangen, Germany
[6] Univ Klinikum Essen, Hautklin, Essen, Germany
[7] DKFZ, Heidelberg, Germany
[8] Univ Klinikum Mannheim, Klin Kooperat Einheit Dermatoonkol, Heidelberg, Germany
[9] Univ Klinikum Kiel, Hautklin, Kiel, Germany
[10] Univ Klinikum Koln, Hautklin, Cologne, Germany
[11] Univ Klinikum Mainz, Hautklin, Mainz, Germany
[12] Univ Klinikum Hannover, Hautklin, Hannover, Germany
[13] Charite Univ Klinikum, Hautklin, Berlin, Germany
[14] Univ Munchen LMU, Hautklin, Munich, Germany
[15] Univ Klinikum Marburg, Hautklin, Marburg, Germany
[16] Univ Klinikum Ulm, Hautklin, Ulm, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2016年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FV19
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [41] Spanish Melanoma Multidisciplinary Group (GEM): Longterm survivors treated with ipilimumab (IPI) in the expanded access programme (EAP).
    Hernando, Cristina
    Soriano, Virtudes
    Pablo Berros, Jose
    Maria Arance, Ana
    Mujika, Karmele
    Rodriguez Abreu, Delvys
    Alonso, Lorenzo
    Alonso, Martina
    Yapur, Lorena
    Berrocal, Alfonso
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Avelumab treatment of metastatic merkel cell carcinoma (mMCC): Updated findings from Australian patients enrolled in an expanded access program(EAP)
    Sandhu, Shahneen
    Kasturi, Vijay
    Guminski, Alex
    Steer, Christopher
    Atkinson, Victoria
    Nordman, Ina
    Tobin, Peter
    Reed, Josh
    Costa, Nuno
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 184 - 184
  • [43] Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad hoc expanded access program (EAP)
    Ascierto, P. A.
    Nathan, P.
    Kasturi, V.
    Dirix, L. Y.
    Fenig, E.
    Hennessy, M.
    Reed, J.
    Engelsberg, A.
    Hariharan, S.
    Lebbe, C.
    ANNALS OF ONCOLOGY, 2018, 29 : 29 - 29
  • [44] Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
    Friedman, Claire Frances
    Navid-Azarbaijani, Pedram
    Shoushtari, Alexander Noor
    Campbell, Shonnette C.
    Callahan, Margaret K.
    Momtaz, Parisa
    Prempeh-Keteku, Nana A.
    Postow, Michael Andrew
    Shames, Yelena
    Wolchok, Jedd D.
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] EXPANDED ACCESS PROGRAM (EAP) FOR LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Palumbo, A.
    Gay, F.
    Buda, G.
    Guglielmelli, T.
    Perrone, G.
    Corradini, P.
    Benedetti, F.
    Offidani, M.
    Rossi, D.
    Gozzetti, A.
    Catalano, L.
    Canepa, L.
    Di Raimondo, F.
    Patriarca, F.
    Petrucci, M. T.
    Di Renzo, N.
    Galli, M.
    Cavallo, F.
    Bringhen, S.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 257 - 257
  • [46] Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC)
    Hoffman-Censits, Jean H.
    Pal, Sumanta K.
    Zheng, Hanzhe
    Tayama, Darren
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results
    Hamid, Omid
    Hwu, Wen-Jen
    Richards, Jon M.
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Sznol, Mario
    Minor, David R.
    Pavlick, Anna C.
    Urba, Walter John
    Hodi, F. Stephen
    Yang, Arvin
    Michener, Tracy
    Balogh, Agnes
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
    Hogg, David
    Chapman, Paul B.
    Sznol, Mario
    Lao, Christopher D.
    Gonzalez, Rene
    Daniels, Gregory A.
    Smylie, Michael
    Kudchadkar, Ragini Reiney
    Thompson, John A.
    Sharfman, William Howard
    Atkins, Michael B.
    Pavlick, Anna C.
    Jiang, Joel
    Avila, Alexandre
    Demelo, Sheena
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy
    Sabbatini, R.
    Galli, L.
    Pignata, S.
    Lo Re, G.
    Valcamonico, F.
    Defferrari, C.
    Spada, M.
    Santini, D.
    Masini, C.
    Ciuffreda, L.
    Ruggeri, E. M.
    Chioni, A.
    Livi, L.
    Fagnani, D.
    Bonetti, A.
    Giustini, L.
    Duranti, S.
    Procopio, G.
    Caserta, C.
    Carteni, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad-hoc expanded access program (EAP)
    Nathan, P.
    Kasturi, V.
    Dirix, L.
    Fenig, E.
    Ascierto, P. A.
    Hennessy, M.
    Reed, J.
    Engelsberg, A.
    Hariharan, S.
    Lebbe, C.
    ANNALS OF ONCOLOGY, 2018, 29
12345